Compare Incyte Corporation (INCY) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Wynn Resorts, Limited — how do they compare? Incyte Corporation trades at $117.91 (market cap $23.11B), while Wynn Resorts, Limited trades at $95.06 (market cap $9.93B). The key difference: Incyte Corporation is far larger — about 2.3× Wynn Resorts, Limited's market cap, and Wynn Resorts, Limited pays a 1.05% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | WYNN | |
|---|---|---|
Market Cap | $23.11B | $9.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $133.34 |
52-Week Low | $67.38 | $94.78 |
Enterprise Value | $19.13B | $20.29B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Wynn Resorts (WYNN) trades at $95.61, down 1.07% today, with a bearish technical signal and mixed earnings history including three consecutive quarterly misses. The company maintains strong revenue growth from $3.8B in 2022 to $7.1B in 2025, though net margins have compressed from 11.17% to 4.58% over the same period. Recent news highlights Q1 2026 earnings beating estimates with $1.25 EPS (Zacks Investment Research, May 7, 2026), while long-term debt remains elevated at $10.50B.
Analyst consensus is bullish with a $135.50 price target (64% buy ratings), but risks include high leverage, margin pressure from Macau competition, and geopolitical challenges for the UAE expansion. The stock offers 42% upside to consensus target if operational execution improves, though investors face volatility from earnings inconsistency and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
